Podium to Practice: Chicago 2025 – Lung: IMforte

Podium to Practice: Chicago 2025 – Lung: IMforte

Podium to Practice: Chicago 2025
Explore more from your favourite experts – click their name to access their entire library of content.
Icon Chair Speaker

Chair

Dr. Barb Melosky

Icon Chair Speaker

Speakers

Dr. Rosalyn Juergens

Dr. Kevin Jao

Studies / Trials Discussed

8006 – Lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC): Primary results of the phase 3 IMforte trial.

This program has been made possible through unrestricted support from Boehringer Ingelheim.

Studies/trials discussed:

8006 – Lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC): Primary results of the phase 3 IMforte trial.
Tagged